Background/Objectives: Clinical tumor sequencing has become central to precision oncology, yet secondary genomic analysis remains heavily dependent on cloud or centralized computational infrastructure, creating barriers related to cost, turnaround time, data governance, and accessibility. We demonstrate that secondary analysis of clinical tumor exomes can be performed entirely within a clinical molecular laboratory using workstation-class GPU hardware, eliminating dependence on external computational infrastructure. Methods: Sequence data generated off site were analyzed on premises with a variant-calling workflow run on benchtop GPU workstations. Accuracy was assessed against the Genome in a Bottle germline and Sequencing Quality Control Phase 2 (SEQC2) HCC1395 somatic reference materials and recall of the variants listed on the clinical molecular reports for 172 institutional colorectal tumor exomes. Results: We analyzed all 172 exomes from reads to called variants on device, at a median of 25.1 min of on-device compute across the 170 exomes with complete timing. On the germline reference material, an F-measure of 0.9963 was obtained genome-wide, and 0.9945 restricted to the exome target. Against those reports, we recovered all 153 reported variants across the four driver genes (KRAS, NRAS, PIK3CA, and BRAF). Coding-variant recall on this development cohort was 95.74% (1168/1220) requiring exact reference and alternate allele agreement, and 98.44% (1201/1220) when 33 indels matching on coding or protein position alone were also counted. Call sets were identical across triplicate runs of five exomes on both devices. Conclusions: Secondary analysis of solid tumor exomes was completed on workstation-class hardware in a colorectal cancer cohort, showing that clinical molecular laboratories can independently perform this step without reliance on external computing resources. The architecture, in which each site analyzes its own reads, can serve as a node in a federated genomic system.
28 September 2026 in Proceedings of the National Academy of Sciences
Bcl-2-associated athanogene 3 (BAG3) is a mediator of chaperone-assisted selective autophagy, and in the brain, is most highly expressed in astrocytes. However, its role in astrocytes remains poorly defined. Given the genetic and pathological links of BAG3 to proteostasis and neurodegenerative diseases, we investigated how BAG3 contributes to astrocyte function and Alzheimer’s disease (AD). To define its function and relevance, we used single-nucleus RNA sequencing to confirm BAG3 enrichment in astrocytes and employed CRISPR/Cas9 editing of human induced pluripotent stem cells followed by proteomic and transcriptomic profiling, which revealed that BAG3 loss caused greater disruption in astrocytes than in neurons. BAG3-deficient astrocytes displayed reduced autophagy, lysosomal abundance and activity, and proteasome function. Coimmunoprecipitation identified BAG3 known binding partners (e.g., HSPB8, proteasome regulators), as well as an interactor in the retromer complex, VPS35. BAG3 deficiency resulted in altered retromer activity as measured by amyloid precursor protein (APP) localization in endosomes. In addition to validating these binding partners, integrative -omics analyses showed that BAG3 regulates AD-relevant proteins (GFAP, BIN1), as well as HSPB8. Functionally, BAG3 knockout astrocytes exhibited impaired amyloid-β proteostasis when cocultured with APP/PSEN1 mutant neurons, directly linking BAG3 to a disease-relevant astrocyte phenotype. Finally, analysis of postmortem human brain revealed that BAG3 expression marks a stress-responsive astrocyte subtype in aged individuals. Together, these findings demonstrate that BAG3 coordinates astrocyte proteostasis through interactions with regulators of autophagy, proteasome activity, and retromer function, positioning it as a potential therapeutic target and central node of astrocytic protein quality control in neurodegeneration.